Citation: Df. Hayes, DETERMINATION OF CLINICAL UTILITY OF TUMOR-MARKERS - A TUMOR-MARKER UTILITY GRADING SYSTEM, European journal of cancer, 34, 1998, pp. 10-10
Authors:
JACOBS TW
SIZIOPIKOU KP
PRIOLEAU JE
RAZA S
BAUM JK
HAYES DF
SCHNITT SJ
Citation: Tw. Jacobs et al., DO PROGNOSTIC MARKER STUDIES ON CORE NEEDLE-BIOPSY SPECIMENS OF BREAST-CARCINOMA ACCURATELY REFLECT THE MARKER STATUS OF THE TUMOR, Modern pathology, 11(3), 1998, pp. 259-264
Authors:
PEGRAM MD
LIPTON A
HAYES DF
WEBER BL
BASELGA JM
TRIPATHY D
BALY D
BAUGHMAN SA
TWADDELL T
GLASPY JA
SLAMON DJ
Citation: Md. Pegram et al., PHASE-II STUDY OF RECEPTOR-ENHANCED CHEMOSENSITIVITY USING RECOMBINANT HUMANIZED ANTI-P185(HER2 NEU) MONOCLONAL-ANTIBODY PLUS CISPLATIN IN PATIENTS WITH HER2/NEU-OVEREXPRESSING METASTATIC BREAST-CANCER REFRACTORY TO CHEMOTHERAPY TREATMENT/, Journal of clinical oncology, 16(8), 1998, pp. 2659-2671
Authors:
BAST RC
DESCH CE
HAYES DF
KEMENY NE
RAVDIN P
SOMERFIELD MR
SMITH TJ
Citation: Rc. Bast et al., 1997 UPDATE OF RECOMMENDATIONS FOR THE USE OF TUMOR-MARKERS IN BREASTAND COLORECTAL-CANCER, Journal of clinical oncology, 16(2), 1998, pp. 793-795
Authors:
SHAPIRO CL
HARDENBERGH PH
GELMAN R
BLANKS D
HAUPTMAN P
RECHT A
HAYES DF
HARRIS J
HENDERSON IC
Citation: Cl. Shapiro et al., CARDIAC EFFECTS OF ADJUVANT DOXORUBICIN AND RADIATION-THERAPY IN BREAST-CANCER PATIENTS, Journal of clinical oncology, 16(11), 1998, pp. 3493-3501
Authors:
YAMAUCHI H
ONEILL A
GELMAN R
CARNEY W
TENNEY DY
HOSCH S
HAYES DF
Citation: H. Yamauchi et al., PREDICTION OF RESPONSE TO ANTIESTROGEN THERAPY IN ADVANCED BREAST-CANCER PATIENTS BY PRETREATMENT CIRCULATING LEVELS OF EXTRACELLULAR DOMAIN OF THE HER-2 C-NEU PROTEIN/, Journal of clinical oncology, 15(7), 1997, pp. 2518-2525
Authors:
JACOBS TW
SIZIOPIKOU KP
PRIOLEAU JE
RAZA S
BAUM JK
HAYES DF
SCHNITT SJ
Citation: Tw. Jacobs et al., DO PROGNOSTIC MARKER STUDIES ON BREAST CORE NEEDLE-BIOPSY SPECIMENS ACCURATELY REFLECT THE MARKER STATUS OF THE TUMOR, Laboratory investigation, 76(1), 1997, pp. 97-97
Authors:
HAYES DF
BAST RC
DESCH CE
FRITSCHE H
KEMENY NE
JESSUP JM
LOCKER GY
MACDONALD JS
MENNEL RG
NORTON L
RAVDIN P
TAUBE S
WINN RJ
Citation: Df. Hayes et al., TUMOR-MARKER UTILITY GRADING SYSTEM - A FRAMEWORK TO EVALUATE CLINICAL UTILITY OF TUMOR-MARKERS, Journal of the National Cancer Institute, 88(20), 1996, pp. 1456-1466
Authors:
GIMMI CD
MORRISON BW
MAINPRICE BA
GRIBBEN JG
BOUSSIOTIS VA
FREEMAN GJ
PARK SYL
WATANABE M
GONG JL
HAYES DF
KUFE DW
NADLER LM
Citation: Cd. Gimmi et al., BREAST CANCER-ASSOCIATED ANTIGEN, DF3 MUC1, INDUCES APOPTOSIS OF ACTIVATED HUMAN T-CELLS/, Nature medicine, 2(12), 1996, pp. 1367-1370
Authors:
BAST RC
BATES S
BREDT AB
DESCH CE
FRITSCHE H
FUES L
HAYES DF
KEMENY NE
KRAGEN M
JESSUP J
LOCKER GY
MACDONALD JS
MENNEL RG
NORTON L
RAVDIN P
SMITH TJ
TAUBE S
WINN RJ
Citation: Rc. Bast et al., CLINICAL-PRACTICE GUIDELINES FOR THE USE OF TUMOR-MARKERS IN BREAST AND COLORECTAL-CANCER, Journal of clinical oncology, 14(10), 1996, pp. 2843-2877
Authors:
RECHT A
COME SE
HENDERSON IC
GELMAN RS
SILVER B
HAYES DF
SHULMAN LN
HARRIS JR
Citation: A. Recht et al., THE SEQUENCING OF CHEMOTHERAPY AND RADIATION-THERAPY AFTER CONSERVATIVE SURGERY FOR EARLY-STAGE BREAST-CANCER, The New England journal of medicine, 334(21), 1996, pp. 1356-1361
Authors:
COSTA JJ
DEMETRI GD
HARRIST TJ
DVORAK AM
HAYES DF
MERICA EA
MENCHACA DM
GRINGERI AJ
SCHWARTZ LB
GALLI SJ
Citation: Jj. Costa et al., RECOMBINANT HUMAN STEM-CELL FACTOR (KIT-LIGAND) PROMOTES HUMAN MAST-CELL AND MELANOCYTE HYPERPLASIA AND FUNCTIONAL ACTIVATION IN-VIVO, The Journal of experimental medicine, 183(6), 1996, pp. 2681-2686
Authors:
SHAPIRO CL
DEZUBE BJ
TRETYAKOV O
WRIGHT J
CAP B
HENDERSON IC
HAYES DF
Citation: Cl. Shapiro et al., DOSE-ESCALATION OF N,N',N''-TRIETHYLENETHIOPHOSPHORAMIDE COMBINED WITH PENTOXIFYLLINE FOR ADVANCED BREAST-CANCER, Clinical cancer research, 1(8), 1995, pp. 791-796
Citation: Cm. Legler et Df. Hayes, DOXORUBICIN FOR INFLAMMATORY BREAST-CANCER - A RED HUMOR FOR A RED TUMOR, Annals of surgical oncology, 2(4), 1995, pp. 283-285
Authors:
VOGEL CL
SCHOENFELDER J
SHEMANO I
HAYES DF
GAMS RA
Citation: Cl. Vogel et al., WORSENING BONE-SCAN IN THE EVALUATION OF ANTITUMOR RESPONSE DURING HORMONAL-THERAPY OF BREAST-CANCER, Journal of clinical oncology, 13(5), 1995, pp. 1123-1128
Authors:
HAYES DF
VANZYL JA
HACKING A
GOEDHALS L
BEZWODA WR
MAILLIARD JA
JONES SE
VOGEL CL
BERRIS RF
SHEMANO I
SCHOENFELDER J
Citation: Df. Hayes et al., RANDOMIZED COMPARISON OF TAMOXIFEN AND 2 SEPARATE DOSES OF TOREMIFENEIN POSTMENOPAUSAL PATIENTS WITH METASTATIC BREAST-CANCER, Journal of clinical oncology, 13(10), 1995, pp. 2556-2566
Authors:
HARRIST TJ
COSTA JJ
DEMETRI GD
DVORAK AM
HAYES DF
MERICA EA
MENCHACA D
GRINGERI AJ
GALLI SJ
Citation: Tj. Harrist et al., RECOMBINANT HUMAN STEM-CELL FACTOR (SCF) (C-KIT LIGAND) PROMOTES MELANOCYTE HYPERPLASIA AND ACTIVATION IN-VIVO, Laboratory investigation, 72(1), 1995, pp. 48-48
Authors:
NGUYEN M
WATANABE H
BUDSON AE
RICHIE JP
HAYES DF
FOLKMAN J
Citation: M. Nguyen et al., ELEVATED LEVELS OF AN ANGIOGENIC PEPTIDE, BASIC FIBROBLAST GROWTH-FACTOR, IN THE URINE OF PATIENTS WITH A WIDE SPECTRUM OF CANCERS, Journal of the National Cancer Institute, 86(5), 1994, pp. 356-361
Citation: Df. Hayes, TUMOR-MARKERS FOR BREAST-CANCER - CURRENT UTILITIES AND FUTURE-PROSPECTS, Hematology/oncology clinics of North America, 8(3), 1994, pp. 485-506
Citation: Df. Hayes, TUMOR-MARKERS IN ADULT SOLID MALIGNANCIES - PREFACE, Hematology/oncology clinics of North America, 8(3), 1994, pp. 180000009-180000010